Study | Selection | Comparability | Outcome | NOS score |
|---|
Crepaz | 3 | 1 | 3 | 7 |
Serino | 3 | 1 | 2 | 6 |
D’alto | 3 | 2 | 2 | 7 |
Kaya | 3 | 2 | 3 | 8 |
Duffels | 3 | 1 | 2 | 6 |
Zuckerman | 3 | 2 | 3 | 8 |
Zhang | 3 | 1 | 2 | 6 |
Chon | 3 | 1 | 2 | 6 |
Fernandes | 3 | 1 | 3 | 7 |
- Note: Newcastle-Ottawa (NOS) cohort study quality assessment list was used to evaluate the quality of non-randomized controlled trials. The total score was defined as 9 points, and ≥ 7 points indicated low risk. Comparability: (1) Study the control of single targeted drug therapy for PAH; (2) The study controlled for any other confounding factors (controlling for the inclusion of subjects with no other genetic metabolic disease, such as DS)
